Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Healthcare Biotechnology

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by lv_426on Aug 10, 2019 12:42pm

49 Views

Post# 30014552

RE:RE:RE:RE:RE:RE:Update

MetzGER wrote: Because Lee has 400.000 stock options. How much else he should have? There is always a little risk that things don’t come like they were planned. Why he should buy stocks if he has so much options?

You're not very bright are you? Options only matter if you cash them in and you would cash them in they are a net benefit for you. Buy shares shows you have confidence in a company, you are spending YOUR money, now. Lee buckler is the CEO and has purchased less than 5000 shares...speaks volumes

Bullboard Posts

Cannabix advances marijuana breathalyzer tech